Licensed vaccine
MENVEO
FDA-licensed vaccine · GlaxoSmithKline Biologicals SA · STN 125300
Key facts
| Trade name | MENVEO |
|---|---|
| Proper name | Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine |
| Manufacturer | GlaxoSmithKline Biologicals SA |
| Submission tracking number (STN) | 125300 |
| Recent FDA documents | August 30, 2024 Approval Letter - MENVEO, October 14, 2022 Approval Letter - MENVEO, July 28, 2020 Approval Letter - MENVEO, February 20, 2020 Approval Letter - MENVEO, December 20, 2019 Approval Letter - MENVEO, September 26, 2019 Approval Letter - MENVEO, October 4, 2018 Approval Letter - MENVEO, Approval History, Letters, Reviews, and Related Documents - Menveo, Package Insert - MENVEO, Supporting Documents older than three years - MENVEO |
| FDA page updated | Sep 6, 2024 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: